MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from publicofferings$12,663K Proceeds from warrantinducement financing$4,136K Proceeds from registereddirect offering$3,503K Proceeds from exercise ofpre-funded warrants$5K Net cash provided byfinancing activities$17,119K Effect of exchange ratechanges on cash$6K Canceled cashflow$3,188K Net increase(decrease) in cash and...$785K Canceled cashflow$16,340K Repayment of principal onrelated party term notes...$2,000K Payment of financingcosts$725K Repayment of principal onrelated party bridge...$200K Repayment of principal onterm notes payable$200K Repayment of financinglease obligations$63K Stock-based compensation$1,658K Depreciation andamortization expense$1,228K Change in fair value ofother liabilities and...$84K Net cash used inoperating activities-$16,249K Net cash used ininvesting activities-$91K Canceled cashflow$2,970K Net loss-$16,004K Accrued expenses andother current...-$1,185K Purchases of machinery andequipment$91K Operating lease right ofuse liability-$1,068K Accounts payable-$924K Prepaid expenses andother current assets$38K
Cash Flow
source: myfinsight.com

Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics, Inc. (CLDI)